Navigation Links
First successful human results achieved: Implantable wireless microchip drug delivery device
Date:2/16/2012

Waltham, Mass. February 16, 2012 MicroCHIPS, Inc., a developer of implantable drug delivery devices and biosensors, announces today the results of the first successful human clinical trial with an implantable, wirelessly controlled and programmable microchip-based drug delivery device. The MicroCHIPS study was published in today's online edition of the journal Science Translational Medicine.

"These data validate the microchip approach to multi-year drug delivery without the need for frequent injections, which can improve the management of many chronic diseases like osteoporosis where adherence to therapy is a significant problem," said study lead author Robert Farra, MicroCHIPS President and Chief Operating Officer. "We look forward to making further progress to advance our first device toward regulatory approvals, as well as developing a range of products for use in important disease areas such as osteoporosis, cardiovascular disease, multiple sclerosis, cancer, and chronic pain."

In the trial, post menopausal women diagnosed with osteoporosis received daily doses of the marketed osteoporosis drug teriparatide through microchip delivery rather than daily injection. The drug released from the implanted microchip demonstrated similar measures of safety and therapeutic levels in blood to what is observed from standard, recommended multiple subcutaneous injections of teriparatide.

In the study, seven osteoporotic postmenopausal patients between the ages of 65 and 70 received the microchip-based implant. The primary objective of the clinical trial was to assess the pharmacokinetics (PK) of the released drug teriparatide from the implanted devices. Safety measures included evaluation of the biological response to the implant and monitoring indicators of toxicity. Secondary objectives were to assess the bioactivity of the drug and to evaluate the reliability and reproducibility of releasing the drug from the device.

'/>"/>
Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Successful human tests for first wirelessly controlled drug-delivery chip
2. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
3. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
4. Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012
5. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
6. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
7. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
8. Waters and NIBRT Complete Work on Worlds First UPLC Glycan Database
9. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
10. First Choice Rehabilitation Specialists Joins Select Medical
11. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology ... today announced that Linda Powers , NW Bio CEO, will ... platform for solid tumor cancers and the Company,s multiple clinical ... , , , DATE: , , , Thursday, ... , , 12:15 PM EDT , , , , ...
(Date:5/6/2015)... SHANGHAI , May 6, 2015 Dr ... institute of Massey University, will deliver a speech at the ... 24-25 at the Shanghai New Expo Center.  ... he will introduce to attendees the topic: ,Potato Starch: ... Bulk-ingredients and Smart Foods., Co-editor of a ...
(Date:5/5/2015)... 5, 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens,  today announced that ... of America Merrill Lynch 2015 Health Care Conference on May ... Encore at the Wynn, Las Vegas NV. ... will be available through the investor relations section of Roka ...
(Date:5/5/2015)... Mass. , May 5, 2015 Psyche ... strategic alliance which offers a first-of-its-kind platform that helps ... access to lab results, transforms the way patients engage ... Luminate Health provides a HIPAA-compliant digital ... to access, manage, and understand their lab results, and ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3
... BOSTON, Jan. 4 PAREXEL International,Corporation (Nasdaq: PRXL ... on Wednesday, January 23, 2008 after the close of ... website at, http://www.parexel.com and on the PR Newswire ... conference call and live webcast at 10:00 a.m. ET,on ...
... SOUTH SAN FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, ... been named,General Counsel, a newly established position, and ... is a global life sciences,executive and corporate attorney ... early-stage companies in the US and,Europe. In the ...
... If Approved for Marketing in the United States, Trade Name Will be ... ... Daiichi Sankyo,Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: ... a New Drug,Application (NDA) for prasugrel to the U.S. Food and Drug ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... in the environmentand in environmental science laboratories. Because they ... and antifungal agents, silver nanoparticles increasingly are being used ... This, in turn, has raised concerns about what happens ... new research paper* adds an additional wrinkle: Nature may ...
... have almost lifted the curtain on the long-awaited era of the ... up a person can be deciphered for about that amount ... article in the current edition of Chemical & Engineering News (C&EN), ... of $100,000, by one conservative estimate, is necessary to analyze that ...
... expensive cancer drugs, dubbed "smart drugs" for their ability to ... are not effective in some patients. In two related studies, ... EGF receptor (EGFR), and found that a decoy receptor might ... intended target. "We know that smart drugs like ...
Cached Biology News:Silver cycle: New evidence for natural synthesis of silver nanoparticles 2Yale researchers explain why cancer 'smart drugs' may not be so smart 2
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: